How big is the Mergers And Acquisitions In The Diabetes Market?

The Mergers And Acquisitions In The Diabetes Market size is expected to reach USD 85.73 billion in 2024 and grow at a CAGR of 3.69% to reach USD 102.76 billion by 2029. Read More

What is the current Mergers And Acquisitions In The Diabetes Market size?

In 2024, the Mergers And Acquisitions In The Diabetes Market size is expected to reach USD 85.73 billion. Read More

Who are the key players in Mergers And Acquisitions In The Diabetes Market?

Eli Lily and Company, Sanofi Aventis, Dexcom, Novo Nordisk and Medtronic are the major companies operating in the Mergers And Acquisitions In The Diabetes Market. Read More

Which is the fastest growing region in Mergers And Acquisitions In The Diabetes Market?

North America is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Mergers And Acquisitions In The Diabetes Market?

In 2024, the North America accounts for the largest market share in Mergers And Acquisitions In The Diabetes Market. Read More

What years does this Mergers And Acquisitions In The Diabetes Market cover, and what was the market size in 2023?

In 2023, the Mergers And Acquisitions In The Diabetes Market size was estimated at USD 82.68 billion. The report covers the Mergers And Acquisitions In The Diabetes Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Mergers And Acquisitions In The Diabetes Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Mergers And Acquisitions In The Diabetes Market Share

Statistics for the 2023 & 2024 Mergers And Acquisitions In The Diabetes market share, created by Mordor Intelligence™ Industry Reports. Mergers And Acquisitions In The Diabetes share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Mergers And Acquisitions In The Diabetes Industry

Some prominent players in the market are Medtronic, Eli Lily, Sanofi, Dexcom, and Novo Nordisk, among others. Mergers and acquisitions between players in the recent past helped companies strengthen their market presence and develop capabilities that are novel to the companies. For instance, in July 2021, Eli Lily and Company announced the acquisition of Protomer Technologies Inc. to focus on advancing glucose-responsive insulins and accelerate the development of next-generation protein therapeutics.